4558.T

The company maintains a market capitalization of ¥2.12 billion and a price-to-earnings ratio of 47.05, indicating a relatively high valuation relative to earnings. Its liquidity position is characterized by ¥1.24 billion in cash and equivalents, but this is offset by ¥1.31 billion in long-term debt, resulting in a net cash position that is negative. The company's price-to-book ratio of 0.84 suggests that the market values the company at a discount to its book value. The debt-to-equity ratio of 0.52 indicates a moderate level of leverage, with total liabilities of ¥2.54 billion and total equity of ¥2.53 billion.

Profitability metrics show a return on equity of 1.79% and a return on assets of 0.89%, both of which are below the typical thresholds for strong performance in the Pharmaceuticals industry. The company's operating income of ¥114 million and net income of ¥45.1 million reflect a narrow margin, with a gross profit of ¥3.65 billion on total revenue of ¥6.31 billion. These figures suggest that the company is generating modest returns relative to its asset base and revenue.

The company's revenue is not segmented by product or geographic region in the available data, making it difficult to assess the concentration of its revenue streams. However, the lack of detailed segment reporting may indicate a relatively undiversified business model or a focus on a single core product line.

Looking ahead, the company's growth trajectory is constrained by its current financial performance. The operating cash flow of ¥31.7 million and free cash flow of ¥63.1 million are relatively low, which may limit the company's ability to invest in new projects or expand its operations. The capital expenditure of -¥25.6 million suggests that the company is not currently investing in new capital assets, which could be a sign of financial conservatism or a lack of growth opportunities.

The company's risk profile is characterized by a medium liquidity risk and a low dilution risk. The key financial flag is the negative net cash position after subtracting total debt, which could pose a challenge if the company needs to access additional financing. The company has not issued any recent equity, and there is no indication of dilution pressure in the near term.

There are no recent events or filings that have been disclosed in the available data, which limits the ability to assess the company's strategic direction or operational changes. The absence of recent transcripts or filings may indicate a lack of public communication or a stable business environment.